Tech Company Financing Transactions
Viracta Therapeutics Funding Round
Viracta Therapeutics closed a $10.7 million funding round on 2/14/2019. Backers included private investors.
Transaction Overview
Company Name
Announced On
2/14/2019
Transaction Type
Venture Equity
Amount
$10,695,495
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 6 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2533 S. Coast Hwy. 101 210
Cardiff, CA 92007
USA
Cardiff, CA 92007
USA
Phone
Website
Email Address
Overview
Viracta is committed to advancing new medicines based on its viral activation therapy approach to benefit patients with viral-associated cancers and other serious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Douglas Faller
Chief Executive Officer
Ivor Royston
Chief Medical Officer
Marshelle Warren
VP - Bus. Development
David Slack
VP - R & D
Robert McRae
Browse more venture capital transactions:
Prev: 2/14/2019: Meritize venture capital transaction
Next: 2/14/2019: InfluxData venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs